Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript

Page 3 of 3

Charles Ferranti: Great. That’s helpful. Thank you all so much.

Operator: Thank you. And I am showing no further questions from our phone lines. I’d now like to turn the conference back over to Howard Robin for any closing remarks.

Howard Robin: Well, thank you, everyone, for joining us today, and we remain focused on executing on the development of REZPEG and our immunology-focused research programs. And I think we have a clearly defined path forward. I’d like to thank all of our employees for their efforts and their hard work, and I want to thank our shareholders for their continued support. So we look forward to providing you with updates on our progress. Stay tuned, and thanks for joining us today.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.

Follow Nektar Therapeutics (NASDAQ:NKTR)

Page 3 of 3